This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
William Studier for development of widely used protein- and RNA-production platform By Corie Lok May 14, 2024 Breadcrumb Home Merkin Prize in Biomedical Technology awarded to F. Merkin Prize in Biomedical Technology for his development of an efficient, scalable method of producing RNA and proteins in the laboratory.
Tensor factorization + single-cell rna-seq By lcopelan@broadinstitute.org August 8, 2024 Tensor factorization + single-cell rna-seq Neriman Tokcan UMass Boston MIA About Current Schedule Video Playlist Resources All talks Contact us MIA Talks Search - Any - Fall 2024 Spring 2024 Fall 2023 Spring 2023 Fall 2022 Spring 2022 Fall 2021 Spring 2021 Fall (..)
But some species control genetic responses another way – via RNA editing. Because the edits are in RNA, and not DNA, they are fleeting. In 2015, the researchers discovered that about 60 percent of the mRNAs in the common squid Doryteuthis pealeii are edited. ’ ” Rosenthal posed.
Prior to 2015, I had a casual relationship, at best, with targeting RNA. Targeting RNA is a Whole New World Then in 2015, I became smitten and eloped with RNA, setting out to build a company devoted to bringing to bear industrial drug discovery concepts and methods on a new problem of drugging RNA with small molecules.
A few years ago, at Arrakis Therapeutics, we set out to conquer a strange new territory, drugging RNA structures with small molecules. In fact, it was these early pharmaceutical successes that gave us the confidence that we would ultimately succeed in systematically drugging a wide range of RNA structures.
I had earlier proposed the use of Palmatine and Silver Nitrate in the efficacy against the RNA structure of the COVID-19 virus. 2015): A new approach to chemotherapy: drug-induced differentiation kills African trypanosomes, Scientific Report. (6):22451. We discovered it is highly effective and environmentally friendly. and Wolfgang, H.
14 TDP-43 is a DNA and RNA binding protein that regulates the expression and splicing of several target transcripts. Many potential toxic effects have been suggested, including the mis-splicing of the Stathmin-2 RNA transcript. Projected Increase in Amyotrophic Lateral Sclerosis from 2015 to 2040.” Nature Communications, vol.
We are moving rapidly toward escape velocity in our RNA expedition at Arrakis. For those of you joining us for the first time, it’s worth a quick look back at why we decided to go all-in on the RNA world, why people thought we were crazy, and why we know we’re not. Our terra firma is small-molecule medicines.
2 AlphaFold 3 has been built to model DNA, RNA and smaller molecules (ligands). Google DeepMind’s new AI can model DNA, RNA, and ‘all life’s molecules’. There are several technologies and specific tools being rolled out in this area. The latest exciting advancement is AlphaFold 3, which was just released. Alphafold 3.0:
Back in 2015, I felt compelled to set out in a new direction in drug discovery. However, in June I happened to attend the Gordon Research Conference on Chemical Biology and High-throughput Chemistry where I saw a session on small molecules and RNA. In 2015, Jim was CSO at Rana Therapeutics, but I had heard that he might be moving on.
Since our company’s founding in 2015, we have taken the long view and been singularly focused on building an extremely flexible and broadly applicable platform that can develop a host of RNA‑targeted small molecules (rSMs) to deliver precision medicines for dozens of targets that have been out of reach for conventional approaches.
In this talk, we are motivated by unsupervised problems that arise in the analysis of single cell RNA sequencing data, where sample splitting does not allow us to avoid double dipping. Unfortunately, in some problems, sample splitting is unattractive or impossible.
In a previous study, we showed that these peptides decorate all cellular RNAs and thus impair the binding of RNA-binding proteins to RNA. Since 2015 Oscar is also the Vice Director of CNIO as well as Director of its Molecular Oncology Programme, and professor at the Karolinska Institute in Sweden.
combinatorial chemistry, human genetics, functional genomics, mRNA, I/O, CRISPR, RNA editing, and many others). Over the past decade (2015-2024), looking only at meaningful exits above $100M values: M&As of private biotechs have had a median and average of $270M and $600M, respectively.
DCD-FG uses a Gaussian non-linear low-rank structural equation model and shows significant improvements compared to state-of-the-art methods in both simulations as well as a recent large-scale single-cell RNA sequencing data set with hundreds of genetic interventions.
Next, to see how their tiny models of the human brain respond to various chemicals, the researchers exposed the neural tissue chips to 60 compounds—about half with known neurotoxic effects, and the rest considered harmless to the brain—and measured the activity of 19,000 genes in each organoid by RNA sequencing. 2015 Sep 21.
Arrakis has gone through many significant transitions since its founding in 2015. Or should I say back to retirement, as he was comfortably relaxing at home back in 2016 when Jen Petter lured him back into the fray with the siren call of developing a new class of RNA-targeted small-molecule medicines here at Arrakis.
The two companies have been in a strategic research collaboration agreement since 2015, focused on using CRISPR Cas-9 to discover new potential treatments. “Then the RNA plus the protein [Cas9] will cut — like a pair of scissors — the DNA at that site, and ideally nowhere else.”.
The researchers first compared the editing efficiency of different versions of IscB when coupled with 'ωRNA,' which guides the enzyme to the right spot on the DNA. A particular variant, named IscB*-ωRNA*, had the highest editing efficiency across multiple different sites in the genome. Read more in Nature Methods.
The researchers first compared the editing efficiency of different versions of IscB when coupled with 'ωRNA,' which guides the enzyme to the right spot on the DNA. A particular variant, named IscB*-ωRNA*, had the highest editing efficiency across multiple different sites in the genome. Read more in Nature Methods.
When doctors sequenced the DNA and RNA found in Alice’s blood and synovial fluid—the liquid that surrounds and lubricates joints—they found abnormally low levels of genes encoding iron-storing proteins and high levels of epidermal growth factor receptor RNA.
The company has established its proprietary ex vivo genome-editing platforms for hematopoietic stem cells and T cells, in vivo therapeutic platform based on RNA base editing, and high-throughput genome-editing screening to discover novel targeted therapies. More information can be found at www.edigene.com.
Their solution was to fuse hairpins, little loops made from RNA or DNA, at various positions along the DNA strand that was being sequenced. In 2015, Oxford Nanopore spun off another company, Metrichor , to provide base-calling algorithms through a web interface.
Comparing genome sequences is important because they provide a 4-letter language in the bases A, C, G, and T (for DNA) or A, C, G, and U (for RNA). The agency started tracking it in 2013, and the spread accelerated in 2015. For those who claim nothing’s being done to prevent future pandemics, please look at GISAID.
Ratcliff, figured this out back in 2015. Made from a Cas9 nickase (the histidine at amino acid position 840 is swapped for an alanine) fused to a reverse transcriptase enzyme (which makes DNA from RNA; transcription in reverse), prime editing clinical trials are expected to begin by 2025. They don’t break off. Cell Systems.
Ratcliff, figured this out back in 2015. Made from a Cas9 nickase (the histidine at amino acid position 840 is swapped for an alanine) fused to a reverse transcriptase enzyme (which makes DNA from RNA; transcription in reverse), prime editing clinical trials are expected to begin by 2025. They don’t break off. Cell Systems.
The central dogma is often depicted as DNA→RNA→protein, but it’s much more: A biophysical marvel inside the smallest of vessels. Eterna is an online game (there’s also an app) where anyone on the internet can solve puzzles by manipulating RNA sequences and simulating the results. Biology is a Burrito.
But before diving into our first “new science” post of 2016, let’s take a quick look back at 2015 and some of its remarkable accomplishments. Four of 2015’s Top 10 featured developments directly benefited from NIH support—including Science’s “Breakthrough of the Year,” the CRISPR/Cas9 gene-editing technique. Protein Cell.
The first reliable protocols to differentiate human iPSCs into PGC-like cells in vitro were published in 2015. Epigenetic CRISPR tools are targeted to a particular DNA sequence using a guide RNA molecule. A meiotic cell nucleus beneath the microscope. Image provided by the author.
kilograms of CO 2 and 330 liters of water to make one kilogram of bananas, according to a 2015 study from Ecuador. In 2016, her team demonstrated that, by adding short snippets of DNA or RNA — which can target and “shut down” the MaMADS regulatory proteins — to bananas, it is possible to slow their ripening.
kilograms of CO 2 and 330 liters of water to make one kilogram of bananas, according to a 2015 study from Ecuador. In 2016, her team demonstrated that, by adding short snippets of DNA or RNA — which can target and “shut down” the MaMADS regulatory proteins — to bananas, it is possible to slow their ripening.
From her first biology course in high school, Rehm loved the logic of genetics: the clear trajectory from a simple code of DNA to RNA to proteins and how disrupting that process could lead to disease. Her mother liked to get things done and made lists for everything, a trait both Rehm and her sister inherited.
The 2014-2015 seasonal vaccine, for instance, was only 19 percent effective due to a mismatch between the selected strain and the circulating one. The World Health Organization selects these strains months in advance based on global surveillance data. And their efficacy varies greatly from one year to the next.
Nature Reviews Molecular Cell Biology (2015). FEMS Yeast Research (2015). Link A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , by Jinek M. Nature Reviews Genetics (2015). Nature (2015). Nature Protocols (2015). PNAS (2015). & Charpentier E. & Arnold F.H.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content